{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:33:44Z","timestamp":1788518024923,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T00:00:00Z","timestamp":1446595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.critrevonc.2015.10.017","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T05:00:20Z","timestamp":1446786020000},"page":"137-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Hepatitis B and cancer: A practical guide for the oncologist"],"prefix":"10.1016","volume":"98","author":[{"given":"Claudia","family":"Bozza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Cinausero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Iacono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.10.017_bib0005","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","article-title":"American society of clinical oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases","volume":"28","author":"Artz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcv.2007.11.017","article-title":"The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting","volume":"41","author":"Barclay","year":"2008","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0168-8278(98)80001-9","article-title":"Impact of HBV, HCV and GBV-C\/HGV on hepatocellular carcinomas in Europe: results of a European concerted action","volume":"29","author":"Br\u00e9chot","year":"1998","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0020","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jhep.2009.05.020","article-title":"Transfusion-transmitted hepatitis B virus infection","volume":"51","author":"Candotti","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0025","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0140-6736(89)90713-7","article-title":"Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection","volume":"2","author":"Carman","year":"1989","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1385\/MO:20:4:385","article-title":"Gemcitabine and reactivation of hepatitis B","volume":"20","author":"Cheong","year":"2003","journal-title":"Med. Oncol. Northwood Lond. Engl."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0035","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1172\/JCI119308","article-title":"Cytotoxic T cells and viral hepatitis","volume":"99","author":"Chisari","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0040","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/hep.1840090319","article-title":"The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic HBsAg carriers","volume":"9","author":"Chu","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0045","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/jmv.22199","article-title":"Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings","volume":"83","author":"Coppola","year":"2011","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jcv.2013.06.020","article-title":"HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient","volume":"58","author":"Coppola","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0055","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2011.35.1635","article-title":"Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors","volume":"29","author":"Day","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0060","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(92)91188-A","article-title":"Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver","volume":"103","author":"De Jongh","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0065","unstructured":"De la Revilla J., Calleja J.L., Abreu L., Cancer treatment in patients with hepatitis. ESMO Handbook: Cancer Treatment in Special Clinical Situations; 2013."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0070","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3109\/10428194.2014.947978","article-title":"Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen","volume":"56","author":"Dominguez","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1743-422X-11-16","article-title":"Development of cost-effective real-time PCR test: to detect a wide range of HBV DNA concentrations in the western Amazon region of Brazil","volume":"11","author":"Dos Santos","year":"2014","journal-title":"Virol. J."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B","volume":"50","author":"European Association For The Study Of The Liver","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0085","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0090","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/0003-4819-94-6-744","article-title":"Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis","volume":"94","author":"Hoofnagle","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0095","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatolology"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0100","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatolology"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2893.2002.00344.x","article-title":"Occult hepatitis B virus infection and its clinical implications","volume":"9","author":"Hu","year":"2002","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0110","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1200\/JOP.2013.001215","article-title":"Hepatitis C virus screening in patients with cancer receiving chemotherapy","volume":"10","author":"Hwang","year":"2014","journal-title":"J. Oncol. Pract. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jvh.12305","article-title":"Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases","volume":"22","author":"Hwang","year":"2015","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2362.1994.tb01055.x","article-title":"T cell recognition of hepatitis B and C viral antigens","volume":"24","author":"Jung","year":"1994","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0125","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1365-2036.2006.03081.x","article-title":"Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection","volume":"24","author":"Kohrt","year":"2006","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0130","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4254\/wjh.v6.i12.860","article-title":"Occult hepatitis B virus infection","volume":"6","author":"Kwak","year":"2014","journal-title":"World J. Hepatol"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0135","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V99.7.2324","article-title":"High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation","volume":"99","author":"Lau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0140","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2015.10.017_bib0145","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1386-6532(05)00384-7","article-title":"Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention","volume":"34","author":"Lavanchy","year":"2005","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0150","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00277-003-0825-8","article-title":"Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy","volume":"83","author":"Leaw","year":"2004","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0155","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1440-1746.2003.02976.x","article-title":"Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy","volume":"18","author":"Liaw","year":"2003","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0160","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jfma.2012.10.007","article-title":"The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis","volume":"114","author":"Liu","year":"2015","journal-title":"J. Formos Med. Assoc. Taiwan Yi Zhi"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0165","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0170","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/0016-5085(87)90613-5","article-title":"Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection","volume":"92","author":"Lok","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0175","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/hep.1840080411","article-title":"Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs","volume":"8","author":"Lok","year":"1988","journal-title":"Hepatolology"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0185","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","article-title":"Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients","volume":"57","author":"Mahale","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0190","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7326\/0003-4819-112-3-227","article-title":"Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy","volume":"112","author":"Marcellin","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1478-3231.2007.01618.x","article-title":"Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis","volume":"28","author":"Martyak","year":"2008","journal-title":"Liver Int."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0200","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/0016-5085(94)90761-7","article-title":"Distinguishing between acute and symptomatic chronic hepatitis B virus infection","volume":"106","author":"Maruyama","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2105\/AJPH.89.1.14","article-title":"Prevalence of hepatitis B virus infection in the United States: the national health and nutrition examination surveys, 1976 through 1994","volume":"89","author":"McQuillan","year":"1999","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0210","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7150\/jca.6231","article-title":"The safety of chemotherapy for breast cancer patients with hepatitis C virus infection","volume":"4","author":"Miura","year":"2013","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0215","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/annonc\/mdp458","article-title":"Effects of chronic hepatitis C infection on the treatment of breast cancer patients","volume":"21","author":"Morrow","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0220","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients","volume":"89","author":"Pei","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0225","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0230","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","article-title":"Occult hepatitis B virus infection","volume":"46","author":"Raimondo","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0235","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","article-title":"Statements from the taormina expert meeting on occult hepatitis B virus infection","volume":"49","author":"Raimondo","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00281-012-0327-7","article-title":"Occult HBV infection","volume":"35","author":"Raimondo","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0016-5085(80)90130-4","article-title":"Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection","volume":"79","author":"Realdi","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0250","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3748\/wjg.v18.i14.1616","article-title":"Impact of comorbidities on the severity of chronic hepatitis B at presentation","volume":"18","author":"Sagnelli","year":"2012","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0255","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4254\/wjh.v6.i6.384","article-title":"Clinical impact of occult hepatitis B virus infection in immunosuppressed patients","volume":"6","author":"Sagnelli","year":"2014","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0260","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.dld.2013.01.022","article-title":"Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy","volume":"45","author":"Saitta","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0265","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1007\/s10620-010-1413-0","article-title":"Occult hepatitis B: clinical implications and treatment decisions","volume":"55","author":"Schmeltzer","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0270","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4254\/wjh.v5.i1.43","article-title":"Hepatitis B reactivation related to everolimus","volume":"5","author":"Sezgin","year":"2013","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0280","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jjco\/hyr106","article-title":"Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine","volume":"41","author":"Sohn","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0285","first-page":"15","article-title":"The clinical significance of occult HBV infection","volume":"27","author":"Squadrito","year":"2014","journal-title":"Ann. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0290","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.3748\/wjg.v21.i7.2089","article-title":"Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B","volume":"21","author":"Tan","year":"2015","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0295","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1473-3099(02)00345-6","article-title":"Occult hepatitis B","volume":"2","author":"Torbenson","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0300","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0305","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","article-title":"Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer","volume":"9","author":"Torres","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0310","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/BF01318693","article-title":"Clinical significance of concurrent hepatitis B surface antigen and antibody positivity","volume":"31","author":"Tsang","year":"1986","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0315","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejim.2010.04.010","article-title":"Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients","volume":"21","author":"Watanabe","year":"2010","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0320","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0325","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3892\/mmr.2014.1973","article-title":"Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: a novel mechanism of HBV reactivation following anticancer chemotherapy","volume":"9","author":"Xu","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0330","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.3748\/wjg.v20.i22.6716","article-title":"virus reactivation in cancer patients in the era of targeted therapies","volume":"20","author":"Yazici","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0335","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatolology"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0340","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jmv.2060","article-title":"virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis","volume":"65","author":"Yeo","year":"2001","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0345","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study","volume":"70","author":"Yeo","year":"2003","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0350","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/annonc\/mdh430","article-title":"reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy","volume":"15","author":"Yeo","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0355","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0360","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-004-0725-1","article-title":"Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients","volume":"88","author":"Yeo","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2015.10.017_bib0365","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/bjc.2011.4","article-title":"Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy","volume":"104","author":"Yun","year":"2011","journal-title":"Br. J. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T09:11:01Z","timestamp":1567329061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815300664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":73,"alternative-id":["S1040842815300664"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.10.017","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B and cancer: A practical guide for the oncologist","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}